ŘÍHOVÁ, Kamila, Monika DÚCKA, Iva STANICZKOVÁ ZAMBO, Ladislava VYMĚTALOVÁ, Martin ŠRÁMEK, Filip TRČKA, Jan VERNER, Stanislav DRÁPELA, Radek FEDR, Tereza SUCHÁNKOVÁ, Barbora PAVLATOVSKÁ, Eva ONDROUŠKOVÁ, Irena KUBELKOVÁ, Danica ZAPLETALOVÁ, Štěpán TUČEK, Peter MÚDRY, Dagmar ADÁMKOVÁ KRÁKOROVÁ, Lucia KNOPFOVÁ, Jan ŠMARDA, Karel SOUČEK, Lubor BORSIG and Petr BENEŠ. Transcription factor c-Myb: novel prognostic factor in osteosarcoma. Clinical & Experimental Metastasis. Springer, 2022, vol. 39, No 2, p. 375-390. ISSN 0262-0898. Available from: https://dx.doi.org/10.1007/s10585-021-10145-4.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Transcription factor c-Myb: novel prognostic factor in osteosarcoma
Authors ŘÍHOVÁ, Kamila (203 Czech Republic, belonging to the institution), Monika DÚCKA (703 Slovakia, belonging to the institution), Iva STANICZKOVÁ ZAMBO (203 Czech Republic, belonging to the institution), Ladislava VYMĚTALOVÁ (203 Czech Republic, belonging to the institution), Martin ŠRÁMEK (203 Czech Republic, belonging to the institution), Filip TRČKA (203 Czech Republic, belonging to the institution), Jan VERNER (203 Czech Republic, belonging to the institution), Stanislav DRÁPELA (203 Czech Republic, belonging to the institution), Radek FEDR (203 Czech Republic), Tereza SUCHÁNKOVÁ, Barbora PAVLATOVSKÁ (203 Czech Republic, belonging to the institution), Eva ONDROUŠKOVÁ (203 Czech Republic, belonging to the institution), Irena KUBELKOVÁ, Danica ZAPLETALOVÁ (703 Slovakia, belonging to the institution), Štěpán TUČEK, Peter MÚDRY (203 Czech Republic, belonging to the institution), Dagmar ADÁMKOVÁ KRÁKOROVÁ, Lucia KNOPFOVÁ (203 Czech Republic, belonging to the institution), Jan ŠMARDA (203 Czech Republic, belonging to the institution), Karel SOUČEK (203 Czech Republic, belonging to the institution), Lubor BORSIG and Petr BENEŠ (203 Czech Republic, guarantor, belonging to the institution).
Edition Clinical & Experimental Metastasis, Springer, 2022, 0262-0898.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.000
RIV identification code RIV/00216224:14310/22:00125156
Organization unit Faculty of Science
Doi http://dx.doi.org/10.1007/s10585-021-10145-4
UT WoS 000740192800001
Keywords in English c-Myb; Chemoresistance; Metastasis; Osteosarcoma; Prognosis; Proliferation
Tags 14110112, 14110212, 14110321, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Marie Šípková, DiS., učo 437722. Changed: 25/5/2022 10:05.
Abstract
The transcription factor c-Myb is an oncoprotein promoting cell proliferation and survival when aberrantly activated/expressed, thus contributing to malignant transformation. Overexpression of c-Myb has been found in leukemias, breast, colon and adenoid cystic carcinoma. Recent studies revealed its expression also in osteosarcoma cell lines and suggested its functional importance during bone development. However, the relevance of c-Myb in control of osteosarcoma progression remains unknown. A retrospective clinical study was carried out to assess a relationship between c-Myb expression in archival osteosarcoma tissues and prognosis in a cohort of high-grade osteosarcoma patients. In addition, MYB was depleted in metastatic osteosarcoma cell lines SAOS-2 LM5 and 143B and their growth, chemosensitivity, migration and metastatic activity were determined. Immunohistochemical analysis revealed that high c-Myb expression was significantly associated with poor overall survival in the cohort and metastatic progression in young patients. Increased level of c-Myb was detected in metastatic osteosarcoma cell lines and its depletion suppressed their growth, colony-forming capacity, migration and chemoresistance in vitro in a cell line-dependent manner. MYB knock-out resulted in reduced metastatic activity of both SAOS-2 LM5 and 143B cell lines in immunodeficient mice. Transcriptomic analysis revealed the c-Myb-driven functional programs enriched for genes involved in the regulation of cell growth, stress response, cell adhesion and cell differentiation/morphogenesis. Wnt signaling pathway was identified as c-Myb target in osteosarcoma cells. Taken together, we identified c-Myb as a negative prognostic factor in osteosarcoma and showed its involvement in the regulation of osteosarcoma cell growth, chemosensitivity, migration and metastatic activity.
Links
NV18-07-00073, research and development projectName: c-Myb a jeho transkripční program ve fyziologických a patologických osteogenních procesech
Investor: Ministry of Health of the CR
PrintDisplayed: 19/7/2024 05:52